If you have been reading about pentadecapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
== Sources == Latimer WM and Rodebush WH. (1920) "Polarity and Ionization from the Standpoint of the Lewis Theory of Valence", J. Am. Chem. Soc., 42, 1419–1433. Huggins ML. (1936) J. Org. Chem., 1, 407–456. Pauling L and Niemann C. (1939) J. Am. Chem. Soc., 61, 1860–1867. Huggins M. (1943) "The structure of fibrous proteins", Chem. Rev., 32, 195–218. Huggins ML. (1971) Angew. Chem. Int. Ed., 10, 147–152. Huggins ML. (1980) Chem. Tech., 10, 422.
An old qualitative test for the presence of the alkene functional group is that alkenes turn brown aqueous bromine solutions colourless, forming a bromohydrin with some of the dibromoalkane also produced. The reaction passes through a short-lived strongly electrophilic bromonium intermediate. This is an example of a halogen addition reaction.
== Properties == A single-domain antibody is a peptide chain of about 110 amino acids long, comprising one variable domain (VH) of a heavy-chain antibody, or of a common IgG. These peptides have similar affinity to antigens as whole antibodies, but are more heat-resistant and stable towards detergents and high concentrations of urea. Those derived from camelid and fish antibodies are less lipophilic and more soluble in water, owing to their complementarity-determining region 3 (CDR3), which forms an extended loop (coloured orange in the ribbon diagram above) covering the lipophilic site that normally binds to a light chain. In contrast to common antibodies, two out of six single-domain antibodies survived a temperature of 90 °C (194 °F) without losing their ability to bind antigens in a 1999 study. Stability towards gastric acid and proteases depends on the amino acid sequence. Some species have been shown to be active in the intestine after oral application, but their low absorption from the gut impedes the development of systemically active orally administered single-domain antibodies.
Sources: en.wikipedia.org
Enzyme-linked receptors (or catalytic receptors) are transmembrane receptors that, upon activation by an extracellular ligand, causes enzymatic activity on the intracellular side. Hence a catalytic receptor is an integral membrane protein possessing both enzymatic, catalytic, and receptor functions. They have two important domains, an extra-cellular ligand binding domain and an intracellular domain, which has a catalytic function; and a single transmembrane helix. The signaling molecule binds to the receptor on the outside of the cell and causes a conformational change on the catalytic function located on the receptor inside the cell. Examples of the enzymatic activity include:
=== Towards separation === After Slovenia and Croatia declared independence from the Socialist Federal Republic of Yugoslavia in 1991, Bosnia and Herzegovina declared its sovereignty in October 1991 and organized a referendum on independence in March 1992. The decision of the Parliament of the Socialist Republic of Bosnia and Herzegovina on holding the referendum was taken after the majority of Bosnian Serb members had left the assembly in protest. These Bosnian Serb assembly members invited the Bosnian Serb population to boycott the referendum held on 29 February and 1 March 1992. The turnout in the referendum was 64-67% and the vote was 98% in favor of independence. Independence was declared on 5 March 1992 by the parliament. The referendum and the murder of two Bosnian Serb members of a wedding procession in Sarajevo the day prior to the referendum was utilized by the Bosnian Serb political leadership as a reason to start road blockades in protest. Further political and social deterioration followed, leading to the Bosnian War. The Socialist Republic of Bosnia and Herzegovina was renamed the Republic of Bosnia and Herzegovina on 8 April 1992, losing the adjective "Socialist". It began moving toward a fully capitalist economic system. The republic retained socialist realist symbols pending the end of the Yugoslav Wars. The republic was led by Alija Izetbegović in a fractious political environment. In 1992, the Republic declared independence from the Socialist Federal Republic of Yugoslavia.
=== Number of vibrational modes === In order for a vibrational mode in a sample to be "IR active", it must be associated with changes in the molecular dipole moment. A permanent dipole is not necessary, as the rule requires only a change in dipole moment. A molecule can vibrate in many ways, and each way is called a vibrational mode. For molecules with N number of atoms, geometrically linear molecules have 3N – 5 degrees of vibrational modes, whereas nonlinear molecules have 3N – 6 degrees of vibrational modes (also called vibrational degrees of freedom). As examples linear carbon dioxide (CO2) has 3 × 3 – 5 = 4, while non-linear water (H2O), has only 3 × 3 – 6 = 3.
In contrast, on the same day Medtronic's capitalization was listed on Bloomberg at just over $130 billion (or €115 billion). Medtronic's acquisition of Covidien made Medtronic the world's largest medical device company by revenues.
Sources: en.wikipedia.org
These molecules have been applied to studies in several model organisms, including mice, zebrafish, frogs and sea urchins. Morpholinos can also modify the splicing of pre-mRNA or inhibit the maturation and activity of miRNA. Techniques for targeting Morpholinos to RNAs and delivering Morpholinos into cells have recently been reviewed in a journal article and in book form.
Anopheles arabiensis Patton, 1905 Anopheles bwambae White, 1985 Anopheles melas Theobald, 1903 Anopheles merus Dönitz, 1902 Anopheles quadriannulatus (Theobald, 1911) Anopheles gambiae Giles, 1902 sensu stricto (s.s.) Anopheles coluzzii Coetzee & Wilkerson in Coetzee et al., 2013 Anopheles amharicus Hunt, Wilkerson & Coetzee in Coetzee et al., 2013 The individual species of the complex are morphologically difficult to distinguish from each other, although it is possible for larvae and adult females. The species exhibit different behavioural traits. For example, Anopheles quadriannulatus is both a saltwater and mineralwater species. A. melas and A. merus are saltwater species, while the remainder are freshwater species. Anopheles quadriannulatus generally takes its blood meal from animals (zoophilic), whereas Anopheles gambiae sensu stricto generally feeds on humans, i.e. is considered anthropophilic. Identification to the individual species level using the molecular methods of Scott et al. (1993) can have important implications in subsequent control measures.
== Synthetic biology applications == In addition to its use as a naturally occurring probiotic, S. boulardii has attracted increasing interest as a chassis organism for synthetic biology and engineered microbial therapeutics. Its ability to survive gastrointestinal conditions, transiently persist in the gut, and its established safety record have motivated efforts to genetically modify S. boulardii for the localized delivery of therapeutic molecules. Engineered strains have been reported to express heterologous proteins such as the anti-inflammatory cytokine interleukin-10 (IL-10), with the aim of reducing intestinal inflammation, as well as peptide hormones including exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist investigated for metabolic and endocrine applications. Other engineered variants have been designed to secrete antimicrobial peptides, toxin-neutralizing enzymes, or immunomodulatory metabolites, or to modulate short-chain fatty acid production. Collectively, these approaches position S. boulardii as a promising platform for next-generation live biotherapeutic products (also called advanced microbiome therapeutics), leveraging synthetic biology to extend its therapeutic potential beyond that of conventional probiotics.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.